Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Single Arm Phase II Study Testing the Tolerability and the Efficacy of Bosutinib step-in Dosing in Chronic Phase CML Patients Intolerant or Refractory to Previous Imatinib, Nilotinib or Dasatinib Therapy

NCT03205267 is registered in ClinicalTrials.gov with University of Bonn as lead sponsor.

NCT NCT03205267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03205267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Single Arm Phase II Study Testing the Tolerability and the Efficacy of Bosutinib step-in Dosing in Chronic Phase CML Patients Intolerant or Refractory to Previous Imatinib, Nilotinib or Dasatinib Therapy
Lead sponsor
University of Bonn
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2016
Completion date
October 31, 2019
Enrollment
127 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukaemia